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age was 53.3 ± 11.21 years, educated till secondary level (39.4%), Malays (44.2%) 
and married for 27.73 ± 12.12 years. Life expectancy gained from vaccination is 13.04 
years and average Quality Adjusted Life-years saved (QALYs) is 24.40 in vaccinated 
versus 6.29 in unvaccinated women. Cost/QALYs saved for Pap smear at base case is 
RM 1214.96/QALYs and RM 1100.01/QALYs at increased screening coverage. In 
HPV vaccination, base case is at RM 35,346.79/QALYs and RM 46,530.08/QALYs 
when vaccination price is increased. In combined strategy, cost/QALYs at base case 
is RM 11,289.58/QALYs; RM 7712.74/QALYs at best case and RM 14,590.37/
QALYs at worst case scenario. Incremental cost-effectiveness ratio (ICER) showed 
that screening at 70% coverage or higher is highly cost effective at RM 946.74 per 
QALYs saved and this is followed by combined strategy at RM 35,346.67 per QALYs 
saved. Budget impact analysis indicated that it cost the government RM 180.4 million 
per year and 2.5% of the national health budget. CONCLUSIONS: Vaccination 
increase life expectancy with better QOL. Cost effective strategies will include increas-
ing the Pap smear coverage to 70% or higher. Since feasibility and long term screening 
adherence is doubtful among Malaysian women; vaccination of young women is more 
cost effective strategy against cervical cancer. 
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OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in 
Thailand for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital 
warts in women age 9 to 26 years. To assess the health and economic impact of the 
quadrivalent (6,11,16,18) HPV vaccine in Thailand. METHODS: A published math-
ematical model of the transmission dynamics of HPV infection and disease was 
adapted for Thailand. Model inputs were used from Thailand or the Asia/Paciﬁ c 
region when available; otherwise, the default values in the original model were used. 
Maintaining current cervical cancer screening practices in Thailand, we evaluated two 
strategies: routine vaccination of females by age 12 (S1), and S1 combined with a 
temporary (5 years) female catch-up program for age 12–24 years (S2). The vaccine 
coverage rates were 70% for the routine and 50% for the catch-up vaccination pro-
grams. The perspective of analysis was health-care system. RESULTS: The most 
effective strategy was S2. Using this strategy over 100 years in the population of 
Thailand, the estimated cumulative percent reduction in incident HPV 6/11/16/18-
related genital warts-female, genital warts-male, cervical intraepithelial neoplasia 
(CIN) grade 1, CIN 2/3, and cervical cancer cases was 72%, 55%, 61%, 63%, and 
48%, respectively. The cost-effectiveness ratios were Thai Baht 145,447 or US$4,453 
(weakly dominated), and Thai Baht 131,845 or US$4,036 per quality-adjusted life-
years (QALY) gained for S1 and S2 compared with no vaccination, respectively. 
CONCLUSIONS: In Thailand, vaccination of females age 12–24 years with a quad-
rivalent (6,11,16,18) HPV vaccine can reduce the incidence of cervical cancer, CIN, 
and genital warts at a cost per QALY ratio within the range typically regarded as 
cost-effective. 
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OBJECTIVES: To estimate the relative cost effectiveness of available contraceptives 
in a paciﬁ c region country (Colombia) from a social perspective. METHODS: A 
Markov model was constructed to simulate costs for 13 contraceptive methods and 
for no contraceptive method over a 10-year period, with a 5% discount rate. Failure 
rates, adverse event rates and resource utilization were derived from literature. Sensi-
tivity analyses were performed on costs and effectiveness rates. RESULTS: The four 
least expensive methods per person month were: copper-T IUD (USD $0.34), vasec-
tomy (USD $1.28), tubal ligation (USD $1.44) and implant (USD $2.19). The cost-
effectiveness analysis of methods to prevent pregnancy showed: the Copper T IUD 
has a ratio of incremental cost-effectiveness (ICER) of USD $5,540 (per month, per 
pregnancy avoided) when it is contrasted with the vasectomy. The Vasectomy is 
dominant compared to tubal ligation, and it presents an ICER of USD $7.371 in 
relation to implant methods. Comparing Copper T with the second most affordable 
reversible method, an ICER of USD $12,033 was obtained. The order of results did 
not change with a discount rate of 0% but were sensitive to the time horizon. CON-
CLUSIONS: Differences in time horizon are inﬂ uential factors that determine the 
dominance of contraceptive methods. It is noteworthy that although the cost of a tubal 
ligation and a vasectomy is the same, the total costs for a vasectomy are lower due 
to reduced complication-related costs. Given that the monthly premium of the com-
pulsory health insurance in Colombia for a woman of childbearing age (19–44 years) 
is USD$22, the value of USD$12,033 or $5540 per month to prevent pregnancy 
through implant or vasectomy is excessive. Therefore, according to the case analysis, 
the Copper T is a cost-effective option for Colombia, including reversible and nonre-
versible methods. 
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OBJECTIVES: Cervical cancer is the second highest incidence of female cancers in 
Malaysia. This can be avoided by Pap smear screening and Human Papillomavirus 
(HPV) vaccination i.e., the bivalent vaccine (BV) and quadrivalent (QV). Three 
programs cost effectiveness (CE) options were compared i.e., screening via Pap smear; 
modeling of HPV vaccination (QV and BV) and combined strategy (screening plus 
vaccination). Scenario based sensitivity analysis using screening population coverage 
(40–80%) and costs of vaccine (RM 100–200/dose) were calculated. METHODS: This 
is a cross sectional study from 2006–2009 and respondents were interviewed from six 
public Gynecology–Oncology hospitals. Methods include experts’ panel discussions 
to estimate treatment costs by severity and direct interviews with respondents using 
costing and quality of life questionnaires. RESULTS: A total of 502 cervical cancer 
patients participated with mean age at 53.3 ± 11.21 years, Malays (44.2%) and 
married for 27.73 ± 12.12 years. Cost/QALYs for Pap smear at base case is RM 
1,214.96/QALYs and RM 1,100.01/QALYs at increased screening coverage. In QV 
only, cost/QALYs saved in base case are at RM 15,662/QALYs and RM 24,203/
QALYs when vaccination price is increased. In BV only; cost/QALYs saved in base 
case is at RM 1359,057/QALYs and RM 2530,017.56/QALYs when vaccination price 
is increased. In QV combined strategy cost/QALYs at base case is RM 4937/QALYs; 
RM 3395/QALYs at best case and RM 7992/QALYs at worst case scenario. In BV 
combined strategy, cost/QALYs at base case is RM 6624/QALYs; RM 4033/QALYs 
at best case and RM 10,543/QALYs at worst case scenario. Incremental cost-
effectiveness ratio (ICER) showed that screening at 70% coverage or higher is highly 
cost effective at RM 946.74 per QALYs saved and this is followed by best case com-
bined strategy with QV at RM 13,000 per QALYs saved. CONCLUSIONS: QV is 
more cost effective than BV. The QV combined strategy is more CE than any method 
except Pap smear screening at high population coverage. 
PIH11
IDENTIFYING COST-EFFECTIVE TREATMENT WITH RALOXIFENE IN 
POSTMENOPAUSAL WOMEN USING RISK ALGORITHMS FOR 
FRACTURES AND INVASIVE BREAST CANCER
Ivergard M1, Strom O1, Borgstrom F1, Burge RT2, Tosteson A3, Kanis JA4
1i3 Innovus, Stockholm, Sweden; 2Eli Lilly & Company, Indianapolis, IN, USA; 3Dartmouth 
Medical School, Hanover, NH, USA; 4WHO Collaborating Centre for Metabolic Bone 
Diseases, Shefﬁ eld, UK
OBJECTIVES: Raloxifene (RLX) reduces the risk of vertebral fractures and invasive 
breast cancer (IBC). The National Osteoporosis Foundation (NOF) has recommended 
a threshold for treatment initiation of 10-year major fracture risk of 20%, but given 
RLX’s beneﬁ cial efﬁ cacy on IBC it may be clinically beneﬁ cial and cost-effective to 
treat women with RLX even if they do not meet this threshold. The aim was to identify 
how 5-year IBC risk affects the cost-effectiveness of treating younger postmenopausal 
women who do not meet the 20% absolute fracture risk threshold with RLX com-
pared to no intervention. METHODS: A micro-simulation model populated with data 
speciﬁ c to American women was used to quantify the costs and beneﬁ ts of 5-year 
treatment with RLX from a societal perspective. Possible events were vertebral frac-
ture, IBC, VTE and death. EQ-5D societal health state values were used to estimate 
quality-adjusted life-years (QALYs). The population was selected based on 10-year 
major fracture risk as estimated with FRAX® (5–19.9%) and 5-year IBC risk as 
estimated with Gail risk model (1–5%). RESULTS: The cost per QALY gained ranged 
from US$17,100 to 93,000. RLX was progressively cost-effective with increasing 
fracture risk and IBC risk holding age constant. At lower fracture risk in combination 
with lower IBC risk or when no preventive RLX effect on IBC was assumed, the 
cost-effectiveness of RLX decreased markedly and was not cost-effective given a 
willingness-to-pay of US$50,000. At fracture risk of 15–19.9% RLX was cost-effective 
also in women at lower IBC risk. CONCLUSIONS: RLX is potentially cost-effective 
in young postmenopausal women at elevated IBC risk who do not meet the suggested 
NOF 10-year fracture threshold. This highlights the importance of considering a 
woman’s full risk proﬁ le when deciding which anti-osteoporosis treatment to 
recommend. 
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OBJECTIVES: The study evaluated the cost effectiveness of the bivalent AS04 adju-
vant vaccine in Slovakia and the correlation between vaccine protection duration and 
incremental cost effectiveness of HPV vaccination of 12-year-old girls with bivalent 
AS04 adjuvant vaccine in Slovakia. METHODS: A 1-year cycle Markov model (20—
health state) used age-speciﬁ c data on dysplasia or cervical cancer. A base case analysis 
assumed 98% vaccine efﬁ cacy against HPV—16/18 and 50% vaccination coverage. 
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Neither cross protection nor herd immunity were assumed in the model. The model 
was run in different horizon (10, 12, 14, 16, 18, 19, 20, 25, 30, 35, 40, 50, 60, 70, 
80, 87 cycles) reﬂ ecting hypothetically an estimated duration of vaccine-induced 
protection. ICER results in different horizon were compared with the λ1 threshold 
(EUR18,000 QALY) valid in Slovakia in 2010. Both future costs and utilities were 
discounted by 5%. Adherence to the three-dosage schedule was 2.6 for the covered 
cohort. A calibration reﬂ ects relevant Slovak statistics. RESULTS: Using real-world 
incidence data on dysplasia and cervical cancer, real local cost data and assuming 
50% vaccination coverage rate, vaccination with bivalent AS04 adjuvant vaccine in 
Slovakia is a cost-effective strategy. Cost/QALY lies well below the local threshold in 
the base case analysis. The results of the secondary analysis showed that the vaccina-
tion value of the incremental cost-effectiveness in different time horizon decreases 
exponentially (horizon/EUR/QALY): 10-year horizon/89778 EUR/QALY, 12/55655, 
14/37383, 16/27207, 18/20262, 19/18028, 20/16076, 25/9903, 30/6825, 
35/5000.40/3873, 50/2643, 60/1938, 70/1613, 80/1514, 87/1510. CONCLUSIONS: 
Taking into account conservative mathematical prediction of 20 years of sustainable 
duration of antibody levels and Slovak threshold, the study indicates a very high 
probability that vaccination of 12-year-old girls with the bivalent AS04 adjuvant 
vaccine in Slovakia is a cost-effective strategy. 
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OBJECTIVES: The publication of results from the Women’s Health Initiative (WHI) 
has led to a drop in the use of hormone therapy (HT) among postmenopausal women. 
This study aimed to compare the magnitude of changes in the utilization of HT before 
and after the WHI report among women with different socioeconomic status in 
Taiwan. METHODS: Women who were aged 40–69 and regular estrogen users for 
menopausal symptom in the Taiwan National Health Insurance (NHI) claims database 
during January to June 2001 were identiﬁ ed as the study subjects (N = 57,358). 
Number of outpatient visits with estrogen prescription, total dosage of estrogen, and 
proportion of oral estrogen dosage to total estrogen dosage, were compared on an 
annual basis, between the pre-WHI period (July 2001–June 2002) and the post-WHI 
period (January 2003–December 2003), using generalize estimating equation models. 
Interaction terms of socioeconomic factors and pre- and post-WHI period were entered 
to examine the differential effects of women’ socioeconomic characteristics on the 
changes of HT use, after adjusting other patients’ and providers’ characteristics. 
RESULTS: Signiﬁ cant decreases in number of outpatient visits with estrogen prescrip-
tions, total dosage of estrogen prescription, and the proportion of oral or injection 
estrogen reduced after WHI (P < 0.0001). However, the extents to which this compli-
ance behavior changes varied by women’ socioeconomic characteristics. Women with 
higher wage income level and living in areas of higher unbanizational levels had lower 
number of outpatient visits with estrogen prescriptions, total dosage of estrogen 
prescription, and proportion of oral or injection estrogen, compared to their counter-
parts. CONCLUSIONS: There seemed to exist discrepancy in the compliance behavior 
of HT use among women with different socioeconomic status after the publication of 
WHI report. Interventions to improve the accessibility of health information among 
less privileged women with which resulted in differential changes in health behavior 
among women in different socioeconomic groups. 
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OBJECTIVES: The objective of this study was to assess the construct validity of the 
EQ-5D instrument among Malaysian population. METHODS: This was a cross-
sectional study conducted among Malaysians adults in the northern states of Malaysia. 
A pre-developed questionnaire consisting of both the EQ-5D and SF-12 items was 
used for data collection. Concurrent and convergent validity of EQ-5D were assessed 
by the use of independent t-test and Pearson correlation. Finally, construct validity 
was assessed using three known relationship. RESULTS: A total of 596 valid question-
naires were received and analyzed. The participants were predominantly female, 
Malay ethnic origin and married, with a mean age of 35.67 years (SD = 12.73). The 
mean EQ-5D score was 0.93 (SD = 0.13) and median of 1 (IQR = 0.15). Majority of 
the participants (73.2%) did not have any problem in all 5 dimensions of the EQ5D 
questionnaire. The mean PCS-12 and MCS-12 scores were 48.9 (SD = 7.4) and 49.1 
(SD = 8.0) respectively. Participants with present disease have lower PCS-12 and 
MCS-12 scores and reported more problems with all of EQ-5D dimensions as well as 
lower EQ-5D and EQ-VAS scores (P < 0.05) as compared to those without disease 
(P < 0.05). Convergent validity was supported by a moderate and positive correlation 
between EQ-5D and EQ-VAS with MCS-12 and PCS-12 scores as well as the stronger 
effect size between PCS-12 and the physical dimensions of EQ-5D as well as between 
MCS-12 with anxiety/depression scores. Construct validity of EQ-5D was conﬁ rmed 
by lower score in anxiety dimension among female and older people (P < 0.05). 
CONCLUSIONS: This study has demonstrated the construct validity of EQ-5D 
among Malaysian population. 
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OBJECTIVES: Family effects and caregiver burden should be included in economic 
evaluations of child health interventions, but the methods to include these effects 
remain understudied. This research explores the sensitivity of three generic instruments 
for preference-weighting health states of family caregivers of children with craniofacial 
malformation (CFM). METHODS: Caregivers of children born with CFM were 
identiﬁ ed through the Arkansas Birth Defects Monitoring System. A survey instrument 
was mailed that included the Health Utilities Index (HUI3), the 6-Dimension Short-
Form (SF-6D), the Quality of Well-being (QWB-SA), and two health-related quality 
of life measures for caregivers: the CES-D and the CarerQol. The HUI3, the SF-6D, 
and the QWB-SA were examined in relation to the CES-D, the CarerQol, and each 
other. RESULTS: Sixty-ﬁ ve parents of minor children responded for a completion rate 
of 57%. The mean SF-6D, HUI3, QWB-SA scores were 0.80, 0.84, 0.67. The mean 
CES-D score was 13.3 with 28.6% of the sample scoring 16 or above—a common 
threshold for depressive symptoms. The mean of the CarerQol was 2.8 (0-not at all 
caregiving burden; 8-much caregiving burden). The correlations of the HUI3 and the 
SF-6D with the CES-D were similar (R2’s of 0.513, 0.511) while the R2 was only 0.230 
for the QWB-SA. There was a signiﬁ cant difference in the preference-weighted scores 
of caregivers scoring 16 and above on both the SF-6D and the HUI3. All three generic 
instruments showed moderate relationships with the CarerQol. CONCLUSIONS: The 
HUI3 and SF-6D are more sensitive among the caregiver group than the QWB-SA. 
They might be appropriate to use in calculating quality-adjusted life-year outcomes 
for caregivers in economic evaluation of child health interventions. Variation of 
preference-weighted scores of the generic instruments in caregivers should be further 
investigated. 
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OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ) was developed to gather 
consumer information about their overall satisfaction with eyelash appearance. The 
ESQ was not available in Chinese and therefore needed to be translated and validated. 
METHODS: Following the translation of the ESQ using a forward-backward meth-
odology, the ESQ (23 items) was cognitively debriefed and assessed for relevance in 
15 Chinese women. It was scored according to the developers’ recommendation. Vali-
dation of the ESQ in 150 women consisted of the evaluation of ﬂ oor/ceiling effects, 
internal consistency reliability, item-item correlations, multitrait analysis, test–retest, 
and known-groups methods for comparing subject groups. The 9-item ESQ (ESQ-9) 
was also evaluated using the same psychometric methods. RESULTS: Chinese women 
found the 23 items of the ESQ relevant and acceptable. In the ESQ, the Length, Full-
ness, Overall Satisfaction (LFOS) domain had no difﬁ culties replicating its structure, 
and only one item each in the Conﬁ dence, Attractiveness, and Professionalism (CAP) 
and Daily Routine (DR) domains was problematic. The reduced ESQ-9 had no ﬂ oor 
or ceiling effects, had acceptable internal consistency reliability (α: 0.76–0.86), and 
good test–retest reliability (ICC: 0.86–0.89). Item convergent and discriminant validity 
for the ESQ-9 were very good with all items correlating with their own scale greater 
than 0.84 and with other scales less than 0.47, with all tests demonstrating similar 
statistics as the original US-English version. Internal consistency was acceptable and 
only slightly lower in the Chinese version than the US-English version. The item 
convergent validity demonstrated much stronger correlations for the DR domain than 
the US-English version. CONCLUSIONS: The ESQ-9 is a valid measure of satisfaction 
with eyelash appearance among Chinese women. Although the full version was accept-
able to women, several items did not ﬁ t well into their respective domains. It is 
therefore recommended that the ESQ-9 be used in studies. 
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OBJECTIVES: 1) To determine the level of satisfaction of general public toward the 
provision of health-care delivery by government hospitals and clinics in the state of 
Penang; and 2) to ﬁ nd out factors that may be associated with the general public’s 
satisfaction toward public health-care delivery in the state of Penang. METHODS: A 
cross-sectional study using a prevalidated survey was undertaken with a convenience 
sample of 1000 residents in the State of Penang, Malaysia. At the end of the survey, 
a total of 771 residents had agreed to participated (response rate of 77.1%). All the 
